Regeneron Pharmaceuticals Inc annual net income for fiscal TTM was $4.4 billion, a decrease of 1.8% from $4.5 billion in fiscal 2025. All figures are reported results from public filings — no estimates or projections.
| Net Income (annual) | TTM → 2026-03-31 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 | 2012-12-31 | 2011-12-31 | 2010-12-31 | 2009-12-31 | 2008-12-31 | 2007-12-31 | 2006-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $4.4B | $4.5B | $4.4B | $4.0B | $4.3B | $8.1B | $3.5B | $2.1B | $2.4B | $1.2B | $896M | $636M | $348M | $424M | $750M | ($222M) | ($104M) | ($68M) | ($83M) | ($106M) | ($102M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Net Income (quarterly) | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
|---|---|---|---|---|---|---|---|---|
| Net Income | $727M | $845M | $1.5B | $1.4B | $809M | $918M | $1.3B | $1.4B |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
More REGN metrics: Revenue · Gross Profit · Operating Income · EPS · EBITDA · Free Cash Flow · Shares Outstanding
All REGN financial statements → Interactive REGN charts →
About TickerBase · Data methodology & sources